The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management

被引:41
作者
Weng, Stanley [1 ,2 ,3 ]
DiNatale, Renzo G. [1 ,2 ,4 ]
Silagy, Andrew [1 ]
Mano, Roy [1 ]
Attalla, Kyrollis [1 ]
Kashani, Mahyar [3 ]
Weiss, Kate [1 ]
Benfante, Nicole E. [1 ,5 ]
Winer, Andrew G. [3 ]
Coleman, Jonathan A. [1 ]
Reuter, Victor E. [6 ]
Russo, Paul [1 ]
Reznik, Ed [4 ,7 ]
Tickoo, Satish K. [6 ]
Hakimi, A. Ari [1 ,2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Immunogen & Precis Oncol Platform, New York, NY 10065 USA
[3] SUNY Downstate Hlth Sci Univ, Dept Urol, Brooklyn, NY USA
[4] Mem Sloan Kettering Canc Ctr, Dept Biostat, Computat Oncol, New York, NY 10065 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA
[6] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA
[7] Mem Sloan Kettering Canc Ctr, Ctr Mol Oncol, New York, NY 10065 USA
关键词
Clear cell papillary; DNA copy number; Genomics; Renal cell carcinoma; PATHOLOGICAL CONCORDANCE; EMPHASIS; DISTINCT; NEOPLASMS; FEATURES; DISEASE; TUMOR;
D O I
10.1016/j.eururo.2020.09.027
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Clear cell papillary renal cell carcinoma (CCPRCC) is a recently described tumor entity. Several questions remain about its epidemiology, molecular features, and clinical behavior. Objective: To comprehensively evaluate clinicopathologic and molecular features of CCPRCC, and compare it with more common kidney cancer subtypes. Design, setting, and participants: We identified 89 CCPRCC patients and compared their clinicopathologic features with 1120 localized clear cell renal cell carcinoma (ccRCC) and 129 type 1 papillary renal cell carcinoma (pRCC) patients. Outcome measurements and statistical analysis: Nonparametric statistical testing was used to compare relevant features between tumor types. Overall, cancer-specific survival (CSS) and metastasis-free survival estimates were calculated from initial diagnosis using the Kaplan-Meier method. Patients with ipsilateral multifocal disease were explored further. A subset of CCPRCC tumors underwent genomic analysis and were compared with other RCC subtypes. Results and limitations: A higher proportion of female (45% vs 32%) and African-American (19% vs 3%) patients were observed in the CCPRCC cohort than in the ccRCC and pRCC cohorts. CCPRCC tumors also had increased odds of presenting with additional ipsilateral masses (odds ratio [OR]: 4.41 [confidence interval {CI}: 2.34, 8.15], p < 0.001) and bilateral disease (OR: 4.80 [CI: 2.40, 9.59], p < 0.001) compared with ccRCC tumors. On molecular analysis, CCPRCC tumors showed fewer somatic aberrations and a greater degree of mitochondrial DNA depletion. In multifocal CCPRCC tumors, histologic concordance among the different renal cell carcinoma masses was estimated at 44% (7/16), and none of the individuals presenting exclusively with CCPRCC tumors developed metastatic disease after 5 yr. In contrast, multifocal tumors with CCPRCC and other nonconcordant histologies were more likely to experience adverse outcomes (CSS, log rank p = 0.034). Conclusions: CCPRCC is characterized by distinct molecular and epidemiologic features that could be used to refine current diagnostic approaches. Although their clinical course is generally indolent, multifocal CCPRCC tumors represent a unique diagnostic challenge. In this context, single-mass biopsies could miss concomitant aggressive disease, with a potential negative impact on patient outcomes. Furthermore, high discordance rates in multifocal CCPRCC tumors have important clinical implications in management. Patient summary: We explored the molecular and clinical features of clear cell papillary renal cell carcinoma (CCPRCC) relative to other kidney cancer subtypes. While CCPRCC generally conveys a good prognosis, additional caution should be taken when it is diagnosed using biopsy if multiple kidney masses are present. (C) 2020 Published by Elsevier B.V. on behalf of European Association of Urology.
引用
收藏
页码:468 / 477
页数:10
相关论文
共 34 条
[1]   Clear-cell papillary renal cell carcinoma: 24 cases of a distinct low-grade renal tumour and a comparative genomic hybridization array study of seven cases [J].
Adam, Julien ;
Couturier, Jerome ;
Molinie, Vincent ;
Vieillefond, Annick ;
Sibony, Mathilde .
HISTOPATHOLOGY, 2011, 58 (07) :1064-1071
[2]   Clear cell papillary renal cell carcinoma: Incidence, morphological features, immunohistochemical profile, and biologic behavior: A single institution study [J].
Alexiev, Borislav A. ;
Drachenberg, Cinthia B. .
PATHOLOGY RESEARCH AND PRACTICE, 2014, 210 (04) :234-241
[3]   Clear Cell-Papillary Renal Cell Carcinoma of the Kidney Not Associated With End-stage Renal Disease Clinicopathologic Correlation With Expanded Immunophenotypic and Molecular Characterization of a Large Cohort With Emphasis on Relationship With Renal Angiomyoadenomatous Tumor [J].
Aron, Manju ;
Chang, Elena ;
Herrera, Loren ;
Hes, Ondrej ;
Hirsch, Michelle S. ;
Comperat, Eva ;
Camparo, Philippe ;
Rao, Priya ;
Picken, Maria ;
Michal, Michal ;
Montironi, Rodolfo ;
Tamboli, Pheroze ;
Monzon, Federico ;
Amin, Mahul B. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (07) :873-888
[4]   Clear Cell Tubulopapillary Renal Cell Carcinoma: A Study of 36 Distinctive Low-grade Epithelial Tumors of the Kidney [J].
Aydin, Hakan ;
Chen, Longwen ;
Cheng, Liang ;
Vaziri, Susan ;
He, Huiying ;
Ganapathi, Ram ;
Delahunt, Brett ;
Magi-Galluzzi, Cristina ;
Zhou, Ming .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2010, 34 (11) :1608-1621
[5]  
Benjamini Y.Hochberg., 1995, Controlling the false discovery rate: a practical and powerful approach to multiple testing, P289, DOI DOI 10.1111/J.2517-6161.1995.TB02031.X
[6]   Genome doubling shapes the evolution and prognosis of advanced cancers [J].
Bielski, Craig M. ;
Zehir, Ahmet ;
Penson, Alexander V. ;
Donoghue, Mark T. A. ;
Chatila, Walid ;
Armenia, Joshua ;
Chang, Matthew T. ;
Schram, Alison M. ;
Jonsson, Philip ;
Bandlamudi, Chaitanya ;
Razavi, Pedram ;
Iyer, Gopa ;
Robson, Mark E. ;
Stadler, Zsofia K. ;
Schultz, Nikolaus ;
Baselga, Jose ;
Solit, David B. ;
Hyman, David M. ;
Berger, Michael F. ;
Taylor, Barry S. .
NATURE GENETICS, 2018, 50 (08) :1189-+
[7]   Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology [J].
Cheng, Donavan T. ;
Mitchell, Talia N. ;
Zehir, Ahmet ;
Shah, Ronak H. ;
Benayed, Ryma ;
Syed, Aijazuddin ;
Chandramohan, Raghu ;
Liu, Zhen Yu ;
Won, Helen H. ;
Scott, Sasinya N. ;
Brannon, A. Rose ;
O'Reilly, Catherine ;
Sadowska, Justyna ;
Casanova, Jacklyn ;
Yannes, Angela ;
Hechtman, Jaclyn F. ;
Yao, Jinjuan ;
Song, Wei ;
Ross, Dara S. ;
Oultache, Alifya ;
Dogan, Snjezana ;
Borsu, Laetitia ;
Hameed, Meera ;
Nafa, Khedoudja ;
Arcila, Maria E. ;
Ladanyi, Marc ;
Berger, Michael F. .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (03) :251-264
[8]   Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma A Clinicopathologic Study of 37 Cases From a Single Institution [J].
Dhakal, Hari P. ;
McKenney, Jesse K. ;
Khor, Li Yan ;
Reynolds, Jordan P. ;
Magi-Galluzzi, Cristina ;
Przybycin, Christopher G. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2016, 40 (02) :141-154
[9]   Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course [J].
DiNatale, Renzo G. ;
Gorelick, Alexander N. ;
Makarov, Vladimir ;
Blum, Kyle A. ;
Silagy, Andrew W. ;
Freeman, Benjamin ;
Chowell, Diego ;
Marcon, Julian ;
Mano, Roy ;
Sanchez, Alex ;
Attalla, Kyrollis ;
Weng, Stanley ;
Voss, Martin ;
Motzer, Robert J. ;
Russo, Paul ;
Coleman, Jonathan A. ;
Reuter, Victor E. ;
Chen, Ying-Bei ;
Chan, Timothy A. ;
Reznik, Ed ;
Tickoo, Satish K. ;
Hakimi, A. Ari .
EUROPEAN UROLOGY FOCUS, 2021, 7 (02) :381-389
[10]   Do Clear Cell Papillary Renal Cell Carcinomas Have Malignant Potential? [J].
Diolombi, Mairo L. ;
Cheng, Liang ;
Argani, Pedram ;
Epstein, Jonathan I. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (12) :1621-1634